
SLEEP
Orexin Receptor Antagonists (DORAs): Belsomra vs Dayvigo vs Quviviq
What orexin receptor antagonists are, how the three FDA-approved DORAs (Belsomra, Dayvigo, Quviviq) compare, what the research shows, side effects, and how they differ from Ambien-type pills.

The Zest Team
· 5 min read
Orexin receptor antagonists are prescription sleep medicines that block orexin, the brain's "stay awake" signal. The ones approved for insomnia block both orexin receptors, so they're called dual orexin receptor antagonists (DORAs). Three are FDA-approved: Belsomra (suvorexant), Dayvigo (lemborexant) and Quviviq (daridorexant).
Here is how DORAs work, how the three compare, what the research shows, their side effects, and how they differ from Ambien-type sleeping pills. This is educational information, not medical advice; talk to a licensed clinician before starting or stopping any medication.
What is an orexin receptor antagonist?
Orexin (also called hypocretin) is made by a small group of brain cells and acts on two receptors, OX1R and OX2R. It holds the brain in a steady awake state during the day and falls at night. An orexin receptor antagonist sits in those receptors and keeps orexin out, which turns the wake signal down so your natural sleep drive can take over.
- Dual orexin receptor antagonists (DORAs) block both receptors. All three drugs approved for insomnia in the U.S. are DORAs.
- Single orexin receptor antagonists (SORAs) block only one receptor. None is approved for insomnia in the U.S.
The opposite approach, switching orexin on, is used for narcolepsy. See our guide to orexin agonists and Orzeyful.

Belsomra vs. Dayvigo vs. Quviviq: the three DORAs compared
| Belsomra | Dayvigo | Quviviq | |
|---|---|---|---|
| Generic name | Suvorexant | Lemborexant | Daridorexant |
| Maker | Merck | Eisai | Idorsia |
| FDA approval | August 2014 | December 2019 | January 2022 |
| Usual dose (label) | 10 mg, up to 20 mg | 5 mg, up to 10 mg | 25 to 50 mg |
| Half-life (label) | About 12 hours | 17 to 19 hours | About 8 hours |
| When to take | Within 30 minutes of bed | Right before bed | Within 30 minutes of bed |
| Controlled substance | Schedule IV | Schedule IV | Schedule IV |
| Generic available | No | No | No |
All three need at least 7 hours in bed after a dose, and all three are off-limits for people with narcolepsy. The biggest practical difference is how long they last: a longer half-life can help with waking late in the night but raises the chance of morning grogginess. Full guides: Belsomra, Dayvigo and Quviviq.

Do DORAs work? What the research shows
A 2025 network meta-analysis in Translational Psychiatry pooled eight trials covering 5,198 adults on daridorexant, lemborexant or suvorexant. Every dose studied beat placebo on falling asleep faster and sleeping longer by self-report. The authors noted there is no evidence that DORAs cause physiological tolerance, withdrawal or rebound insomnia when stopped suddenly, and that they don't disrupt normal sleep stages.
Individual trials found the same direction. In daridorexant's phase 3 trials (Lancet Neurology, 2022), the 50 mg dose cut time awake after first falling asleep by about 23 minutes more than placebo at month 1. Lemborexant's SUNRISE-1 trial (JAMA Network Open, 2019) found it reduced time awake in the second half of the night more than extended-release zolpidem.

DORA side effects
The most common side effect across the class is sleepiness the next day, which is dose-related. In the FDA labels' trial data:
- Belsomra: sleepiness in 7% of people on 15 to 20 mg versus 3% on placebo.
- Dayvigo: sleepiness or fatigue in 6.9% (5 mg) and 9.6% (10 mg) versus 1.3% on placebo.
- Quviviq: headache in 6 to 7% versus 5% on placebo, and sleepiness or fatigue in 5 to 6% versus 4%.
All three labels share the same warnings: next-day impairment (Belsomra 20 mg and Dayvigo 10 mg carry cautions against next-day driving), complex sleep behaviors such as sleep-walking, sleep paralysis and hallucinations around sleep, cataplexy-like weakness, and worsening depression or suicidal thoughts. None of the three carries a boxed warning.
DORAs vs. Z-drugs and benzodiazepines
| DORAs | Z-drugs (Ambien, Lunesta) | Benzodiazepines (temazepam) | |
|---|---|---|---|
| How they work | Block the orexin wake signal | Boost GABA to sedate the brain | Boost GABA to sedate the brain |
| Controlled substance | Schedule IV | Schedule IV | Schedule IV |
| FDA boxed warning | None | Complex sleep behaviors (2019) | Abuse, dependence and withdrawal (2020) |
| Beers Criteria (65+) | Not listed | Avoid | Avoid |
That doesn't make DORAs risk-free: they share warnings about next-day impairment and complex sleep behaviors. But they reach sleep by a different route than the GABA-based pills. More on the older classes: Ambien and benzodiazepines for sleep.
Who are DORAs for?
DORAs are approved for adults who have trouble falling asleep, staying asleep, or both. They aren't for people with narcolepsy, and people with depression, sleep apnea, COPD or liver problems need extra care. Cognitive behavioral therapy for insomnia (CBT-I) remains the first step for chronic insomnia; medication works best alongside it. A clinician can weigh which DORA, if any, fits your sleep pattern and other medications.
Zest RX for sleep. Zest is preparing to launch telehealth for sleep, connecting you with licensed providers who can evaluate whether a prescription option fits your needs. Join Zest RX early access.
More orexin drug guides
- Quviviq (daridorexant) guide
- Belsomra (suvorexant) guide
- Dayvigo (lemborexant) guide
- Orexin agonists and Orzeyful (oveporexton)
Frequently asked questions
What does DORA stand for?
Dual orexin receptor antagonist: a medicine that blocks both orexin receptors (OX1R and OX2R) to turn down the brain's wake signal. Belsomra, Dayvigo and Quviviq are the three approved in the U.S.
Dual orexin receptor antagonist: a medicine that blocks both orexin receptors (OX1R and OX2R) to turn down the brain's wake signal. Belsomra, Dayvigo and Quviviq are the three approved in the U.S.
Are DORAs benzodiazepines?
No. DORAs block orexin, while benzodiazepines and Z-drugs boost GABA, the brain's main calming chemical. They are different drug classes, though all are Schedule IV controlled substances.
No. DORAs block orexin, while benzodiazepines and Z-drugs boost GABA, the brain's main calming chemical. They are different drug classes, though all are Schedule IV controlled substances.
Are DORAs addictive?
They are Schedule IV, meaning a recognized but relatively low potential for misuse. A 2025 meta-analysis found no evidence that DORAs cause physiological tolerance, withdrawal or rebound insomnia when stopped.
They are Schedule IV, meaning a recognized but relatively low potential for misuse. A 2025 meta-analysis found no evidence that DORAs cause physiological tolerance, withdrawal or rebound insomnia when stopped.
Which DORA lasts the longest?
Lemborexant (Dayvigo), with a half-life of 17 to 19 hours on its FDA label, followed by suvorexant (Belsomra) at about 12 hours and daridorexant (Quviviq) at about 8 hours.
Lemborexant (Dayvigo), with a half-life of 17 to 19 hours on its FDA label, followed by suvorexant (Belsomra) at about 12 hours and daridorexant (Quviviq) at about 8 hours.
Is there a generic DORA?
No. As of this writing, Belsomra, Dayvigo and Quviviq are each the only approved version of their drug in the U.S., according to the FDA's Drugs@FDA database.
No. As of this writing, Belsomra, Dayvigo and Quviviq are each the only approved version of their drug in the U.S., according to the FDA's Drugs@FDA database.
Can you take a DORA long term?
Longer studies support use for months: lemborexant's SUNRISE-2 trial ran six months placebo-controlled, and a daridorexant extension study followed people for up to 12 months. How long to take one is a decision for your prescriber.
Longer studies support use for months: lemborexant's SUNRISE-2 trial ran six months placebo-controlled, and a daridorexant extension study followed people for up to 12 months. How long to take one is a decision for your prescriber.
Sources
- BELSOMRA (suvorexant) prescribing information, Merck. DailyMed
- DAYVIGO (lemborexant) prescribing information, Eisai. DailyMed
- QUVIVIQ (daridorexant) prescribing information, Idorsia. DailyMed
- Kishi T, et al. Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant for insomnia: a systematic review and network meta-analysis. Transl Psychiatry. 2025. PubMed
- Mignot E, et al. Safety and efficacy of daridorexant in patients with insomnia disorder. Lancet Neurol. 2022;21(2):125-139. PubMed
- Rosenberg R, et al. Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder. JAMA Netw Open. 2019;2(12):e1918254. PubMed
- 2023 American Geriatrics Society Beers Criteria Update. J Am Geriatr Soc. 2023. PubMed
SLEEP
INSOMNIA
SLEEP MEDICATION


